Pyrrole compound, compositions and process for preparation thereof

1. A composition comprising: saroglitazar magnesium wherein the saroglitazar magnesium has a purity of greater than or equal to 99% by weight; and a dimer compound of Formula (IV), wherein the dimer compound of Formula (IV) is present in the composition in an amount relative to saroglitazar magnesium of less than about 0.3% by weight by area percentage of HPLC.

2. The composition according to claim 1 , wherein the dimer compound of Formula (IV) comprises the structure,

3. A composition comprising: saroglitazar magnesium wherein the saroglitazar magnesium has a purity of greater than or equal to 99% by weight; and a sulfoxide compound of Formula (V), wherein the sulfoxide compound of Formula (V) is present in the composition in an amount relative to saroglitazar magnesium of less than about 0.2% by weight by area percentage of HPLC.

4. The composition according to claim 3 , wherein the sulfoxide compound of Formula (V) comprises the structure,

5. A dimer compound of Formula (IV),

6. The composition according to claim 1 , further comprising a sulfoxide compound of Formula (V), wherein the sulfoxide compound of Formula (V) is present in the composition in an amount relative to saroglitazar magnesium of less than about 0.2% by weight by area percentage of HPLC.

7. The composition according to claim 6 , further comprising one or more impurities wherein the one or more impurities have a RRT at 1.06, 1.27, 1.41 and 1.52, wherein the one or more impurities is present in an amount relative to saroglitazar magnesium of less than about 0.15% by weight by area percentage of HPLC.

8. A pharmaceutical composition comprising saroglitazar magnesium according to claim 1 .

9. A process for the preparation of a substantially pure saroglitazar magnesium, the process comprising:

(a) reacting a hydroxyl compound (A) with a mesylate compound (A1) in a mixture of solvents in the presence of a base to obtain an alkoxy ester compound of Formula (II),

(b) hydrolyzing the alkoxy ester compound of Formula (II) with a base in one or more solvents at a lower temperature to obtain a reaction mixture;

(c) optionally, washing the reaction mixture with one or more solvents to obtain an aqueous layer;

(d) treating the aqueous layer with one or more solvents and adjusting the pH 2.0 to 6.0;

(e) extracting the aqueous layer with one or more solvents to obtain an organic layer;

(f) treating the organic layer with S-(−)-α-methylbenzyl amine to obtain a saroglitazar S-(−)-α-methylbenzyl amine (SMBA) salt of Formula (III);

(g) purifying the saroglitazar SMBA salt with one or more solvents to obtain a pure saroglitazar SMBA salt; and

(h) treating the pure saroglitazar SMBA salt with a magnesium source to obtain the substantially pure saroglitazar magnesium.

10. The process according to claim 9 , wherein the mixture of solvents in step (a) comprises one or more of alcohols selected from methanol, ethanol, isopropanol, 2-propanol, 1-butanol, and t-butyl alcohol; ketones selected from acetone, butanone, and methyl isobutyl ketone; esters selected from ethyl acetate, isopropyl acetate, t-butyl acetate, and isobutyl acetate; chlorinated hydrocarbons selected from methylene dichloride, ethylene dichloride, and chlorobenzene; hydrocarbons selected from pentane, hexane, heptane, and cyclohexane; ethers selected from tetrahydrofuran, 1,4-dioxane, diisopropyl ether, diethyl ether, and methyl tert-butyl ether; or a mixture thereof.

11. The process according to claim 9 , wherein independently the base of step (a) and the base of step (b) comprise one or more of sodium hydroxide, potassium hydroxide, lithium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, potassium hydride, potassium tert-butoxide, and sodium pentoxide.

12. The process according to claim 9 , wherein the one or more solvents in step (c) comprises one or more of water, methanol, ethanol, isopropanol, 2-propanol, 1-butanol, t-butyl alcohol, acetone, butanone, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, isobutyl acetate, methyl t-butyl ether, t-butyl acetate, n-butyl acetate, methylene dichloride, ethylene dichloride, and chlorobenzene, or a mixture thereof.

13. The process according to claim 9 , wherein the one or more solvents in step (g) comprises one or more of water, methanol, ethanol, isopropanol, 2-propanol, 1-butanol, t-butyl alcohol, acetone, butanone, methyl isobutyl ketone, ethyl acetate, isopropyl acetate, isobutyl acetate, methyl t-butyl ether, t-butyl acetate, n-butyl acetate, methylene dichloride, ethylene dichloride, tetrahydrofuran and chlorobenzene, or a mixture thereof.

14. The process according to claim 9 , wherein the magnesium source in step (f) comprises one or more of magnesium hydroxide, magnesium methoxide, magnesium acetate, magnesium chloride, and magnesium metal.

15. The process according to claim 9 , wherein the substantially pure saroglitazar magnesium is an amorphous form, wherein the amorphous form is characterized by a x-ray powder diffraction pattern is substantially similar to that depicted in FIG. 1 .

16. The process according to claim 9 , wherein the saroglitazar SMBA salt of Formula (III) has a purity of greater than or equal to 99% by weight, and the dimer compound of Formula (IV) is present in an amount relative to saroglitazar magnesium of less than about 0.3% or the sulfoxide compound of Formula (V) is present in an amount relative to saroglitazar magnesium of less than about 0.2% by weight by area percentage of HPLC.

17. The process according to claim 9 , wherein the saroglitazar SMBA salt has a purity of greater than or equal to 99% by weight, and wherein one or more impurities having a RRT at 1.06, 1.27, 1.41 and 1.52 are present in an amount relative to the saroglitazar SMBA salt of Formula (III) of less than about 0.1% by weight by area percentage of HPLC.

18. A pharmaceutical composition comprising: saroglitazar magnesium; a dimer compound of Formula (IV); and one or more pharmaceutically acceptable excipients, diluents and carriers.

19. A pharmaceutical composition comprising: saroglitazar magnesium; a sulfoxide compound of Formula (V); and one or more pharmaceutically acceptable excipients, diluents and carriers.

20. A method of treating a condition comprising administering the pharmaceutical composition according to claim 1 , wherein the condition comprises one or more of prophylaxis of obesity, hyperlipidemia, hypercholesteremia, hypertension, atherosclerotic disease events, vascular restenosis, diabetes and to prevent or reduce the risk of developing atherosclerosis, which leads to diseases and conditions selected from arteriosclerotic cardiovascular diseases, stroke, coronary heart diseases, cerebrovascular diseases, peripheral vessel diseases and related disorders.